Tyra Biosciences, Inc. (TYRA) Key Metrics
TYRA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.27B
- Enterprise value
- $1.25B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.5 10-yr median 2.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.75
TYRA key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTYRA valuation Price multiples at each fiscal year-end price.
TYRA returns How much profit the business earns on the capital it uses.
TYRA per-share figures Results divided by the shares outstanding at year-end.
TYRA financial health Debt, liquidity and how easily interest is covered.
TYRA efficiency & capital use Working capital cycle and where the cash goes.
TYRA valuation history
TYRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TYRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TYRA cash returned to shareholders
TYRA price vs earnings per share
TYRA key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $1.57B | $795.3M | $591.5M | $318.3M | $583.1M | — | — |
| Enterprise value | $1.32B | $460.1M | $394.5M | $69.7M | $282.1M | — | — |
| Price / book | 6.0 | 2.3 | 2.9 | 1.2 | 1.9 | — | — |
| Earnings yield | −7.7% | −10.9% | −11.7% | −16.2% | −4.5% | — | — |
| Free cash flow yield | −6.1% | −8.9% | −8.6% | −16.0% | −4.2% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.1% | 0.0% | — | 0.0% | — | — |
| Share price at fiscal year-end | $26.29 | $13.90 | $13.85 | $7.60 | $14.07 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.01 | −$1.51 | −$1.62 | −$1.23 | −$0.63 | −$0.22 | −$0.10 |
| Operating cash flow per share | −$1.60 | −$1.22 | −$1.17 | −$1.20 | −$0.57 | −$0.18 | −$0.06 |
| Free cash flow per share | −$1.60 | −$1.23 | −$1.19 | −$1.21 | −$0.59 | −$0.19 | −$0.06 |
| Cash per share | $4.30 | $5.97 | $4.76 | $6.00 | $7.29 | $0.36 | $0.00 |
| Book value per share | $4.35 | $6.00 | $4.78 | $6.16 | $7.28 | −$0.32 | −$0.11 |
| Tangible book value per share | $4.35 | $6.00 | $4.78 | $6.16 | $7.28 | −$0.32 | −$0.11 |
| Capex per share | $0.00 | $0.01 | $0.02 | $0.01 | $0.02 | $0.01 | $0.00 |
| Debt per share | $0.10 | $0.11 | $0.15 | $0.06 | $0.03 | $0.00 | $0.01 |
| Shares outstanding | 59.6M | 57.2M | 42.7M | 41.9M | 41.4M | 42.5M | 42.5M |
| Change in shares outstanding | +4.2% | +34.0% | +2.0% | +1.1% | −2.6% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −39.8% | −31.6% | −29.9% | −18.5% | −18.1% | — | — |
| Return on invested capital (ROIC) | — | — | −764.3% | −933.3% | — | — | — |
| Return on assets (ROA) | −37.1% | −29.3% | −28.1% | −18.1% | −16.2% | −112.6% | −768.6% |
| Return on tangible assets | −42.4% | −23.8% | −30.6% | −19.4% | −8.5% | −58.2% | −768.6% |
| Financial health | |||||||
| Total debt | $5.8M | $6.2M | $6.5M | $2.6M | $1.2M | $142,000 | $253,000 |
| Cash & short-term investments | $256.0M | $341.4M | $203.5M | $251.2M | $302.2M | $15.2M | $108,000 |
| Net debt | −$250.2M | −$335.2M | −$197.0M | −$248.6M | −$301.0M | −$15.1M | $145,000 |
| Debt / equity | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 | — | — |
| Debt / assets | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 | 0.01 | 0.48 |
| Current ratio | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 | 8.22 | 0.02 |
| Quick ratio | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 | 8.22 | 0.02 |
| Interest coverage | — | — | — | -199.1 | -187.8 | — | — |
| Working capital | $247.4M | $332.9M | $196.3M | $251.6M | $300.4M | $13.4M | −$5.0M |
| Invested capital | $9.0M | $7.9M | $7.3M | $9.2M | $738,000 | −$28.7M | −$4.6M |
| Tangible asset value | $259.2M | $343.2M | $204.3M | $257.8M | $301.7M | −$13.6M | −$4.7M |
| Net current asset value | $242.0M | $327.1M | $190.1M | $248.9M | $299.1M | −$14.4M | −$5.1M |
| Graham net-net per share | $3.90 | $5.64 | $4.27 | $5.80 | $7.17 | −$0.34 | −$0.12 |
| Capital allocation | |||||||
| Share buybacks (net) | $0 | $420,000 | $0 | — | $0 | — | — |
| Capex / depreciation | 0.26 | 1.28 | 2.16 | 1.89 | 4.72 | 6.64 | 2.50 |
| Efficiency | |||||||
| Days payables outstanding | 591.0 | 1,846.8 | 3,002.2 | 1,075.3 | 1,646.4 | 3,848.0 | 14,919.4 |
| Receivables turnover | — | 0.00 | 0.00 | — | — | — | — |
| Payables turnover | 0.62 | 0.20 | 0.12 | 0.34 | 0.22 | 0.09 | 0.02 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $1.4M | $700,000 | — | — | — | — |
| Average payables | $884,000 | $2.6M | $2.9M | $872,000 | $631,500 | $495,500 | $327,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TYRA's annual financial statements (latest annual report filed March 2, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TYRA valuation and financial ratios
Tyra Biosciences earned a return on equity of −39.8% in fiscal 2025. It ended the year with $5.8 million of debt and $256.0 million in cash and short-term investments, a net cash position of $250.2 million. The share count rose 40.1% from 42.5M to 59.6M over 6 years.
See the TYRA income statement, the TYRA chart for price history, or the TYRA stock overview for the latest quote and news.
TYRA key metrics FAQ
What is Tyra Biosciences's return on equity?
Tyra Biosciences's return on equity (ROE) was −39.8% in fiscal 2025: net income of -$119.9 million on average shareholders' equity of $301.2 million.
How much debt does Tyra Biosciences have?
Tyra Biosciences had total debt of $5.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Tyra Biosciences's free cash flow yield?
Tyra Biosciences generated -$95.3 million of free cash flow in fiscal 2025, a free cash flow yield of −6.1% on its market value at year-end ($1.6 billion).
What is Tyra Biosciences's current ratio?
Tyra Biosciences's current ratio was 14.67 at the end of fiscal 2025: current assets were 14.67 times current liabilities.